骨髄増殖性新生物治療の世界市場

骨髄増殖性新生物治療の世界市場は2030年までに105億米ドルに達する見込み

2024年に91億米ドルと推定される骨髄増殖性新生物治療の世界市場は、2024～2030年の分析期間にCAGR 2.4%で成長し、2030年には105億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである本態性血小板血症は、CAGR 2.7%を記録し、分析期間終了時には66億米ドルに達すると予測されます。骨髄線維症セグメントの成長率は、分析期間中CAGR 1.6%と推定されます。

米国市場は25億米ドルと推定、中国はCAGR 4.7％で成長予測

米国の骨髄増殖性新生物治療市場は2024年に25億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 4.7%で推移し、2030年には20億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.9%と1.8%と予測されています。欧州では、ドイツがCAGR 1.3%で成長すると予測されています。

世界の骨髄増殖性新生物治療市場- 主要動向と促進要因まとめ

骨髄増殖性新生物が持続的な治療課題である理由とは？

骨髄増殖性新生物（MPN）は、造血幹細胞の遺伝子変異に起因し、血液細胞の過剰産生をもたらす複雑な血液悪性腫瘍の一群です。真性多血症（PV）、本態性血小板血症（ET）、原発性骨髄線維症（PMF）の3つの典型的なMPNサブタイプは、臨床症状において重大な重複を示すが、高度に個別化された治療アプローチが要求されます。慢性的な病勢進行、頻発する血栓性イベント、急性骨髄性白血病（AML）への転化リスクが、複雑な臨床像に寄与しています。これらの変数は、症状のコントロールと病勢進行の予防のバランスをとらなければならない血液内科医にとって、絶え間ない治療上の課題を浮き彫りにしています。

特にJAK2、CALR、MPL遺伝子における変異の存在がそうです。この遺伝的多様性により、特定の変異プロファイルに合わせた精密医療戦略が必要となります。MPNは慢性疾患であるため、しばしば生涯にわたる管理が必要であり、病態の変化や耐性の発現に応じて治療法も変化します。分子病態の理解が深まるにつれて、治療パラダイムは対症療法から疾患修飾戦略へと移行しつつあります。この進化する治療哲学は、臨床の優先順位を再形成し、JAK阻害だけではない標的治療への需要を高めています。

治療革新はどのように治療戦略を再構築しているのか？

MPN治療における最近の進歩は、新世代の標的薬、特にヤヌスキナーゼ（JAK）阻害薬が中心となっています。ルキソリチニブとフェドラチニブは、効果的な症状緩和と脾臓容積の減少をもたらし、骨髄線維症治療の基礎となっています。しかし、細胞減少や耐性に関連する限界から、作用機序の異なる新規薬剤の追求が促されています。これらの薬剤には、早期PVおよびETに対するインターフェロン、高リスク骨髄線維症に対するイメテルスタットのようなテロメラーゼ阻害剤、遺伝子発現に影響を及ぼすことを目的としたBET阻害剤などがあります。現在後期臨床試験段階にあるこれらの薬剤は、現行のJAK阻害剤に抵抗性を示す患者に対する治療法の選択肢を広げることが期待されます。

さらに、併用療法は耐性を克服し、臨床効果を持続させる手段として注目されつつあります。JAK阻害剤とPI3K、BCL-2、エピジェネティックモジュレーターを併用するような二重経路阻害に関する調査は、より持続的な奏効の可能性を示しています。バイオマーカー主導の薬剤開発はまた、個々の疾患生物学に基づく治療の個別化を目指し、新規試験のための患者選択を洗練させつつあります。このような技術革新は、MPN治療に対するより微妙で層別化されたアプローチへの決定的な転換を意味し、この分野を緩和ではなく真の疾患改善に近づけています。

なぜ診断の精度と患者モニタリングが重要性を増しているのか？

高度な診断技術は、治療方針の決定や病勢進行の評価に重要な役割を果たすようになってきています。次世代シークエンシング（NGS）と分子プロファイリングが利用しやすくなったことで、臨床医はMPNのサブタイプを正確に分類し、高リスクの変異を検出できるようになっています。これらのツールは、予後不良をもたらすASXL1、SRSF2、EZH2などの新たな変異を同定する上で特に有用であり、それによって治療強度と移植適格性に影響を及ぼします。診断の精度は、もはや最初の発見に限定されるものではなく、長期にわたる治療適応を導く上で極めて重要なものとなっています。

さらに、分子生物学的検査による縦断的な疾患モニタリングは、治療反応と進行の評価方法を変えつつあります。対立遺伝子負荷、血液学的パラメーター、骨髄線維化レベルを定期的に追跡することで、治療抵抗性とAMLへの進行を早期に発見することができます。また、測定可能残存病変（MRD）評価の出現は、特に臨床試験の文脈において、治療効果を評価する新たな道を開くものです。このように診断学が治療の意思決定に統合されることで、臨床経過が大きく変わりつつあり、将来の治療アルゴリズムにおいてますます重要な役割を果たすことが期待されています。

骨髄増殖性新生物治療市場の成長の原動力は？

骨髄増殖性新生物治療市場の成長は、技術の進歩、エンドユースの変革、臨床ニーズの進化に根ざしたいくつかの要因によって牽引されています。特にJAK阻害薬や新たな二次治療薬などの標的治療薬の採用が加速していることが、重要な成長の起爆剤となっています。第一世代の治療薬に対する耐性が蔓延する中、作用機序が差別化された革新的な分子のパイプラインが商業的な勢いを増しています。バイオ医薬品各社は、MPN、特に骨髄線維症の自然史を変化させる疾患修飾性治療薬の開発に力を注いでいます。

専門的な血液センターおよび三次医療機関からの需要が増加していることも大きな成長要因であり、これらのセンターでは分子診断や個別化治療プロトコルの導入が進んでいます。標準治療への精密医療の統合は、患者の転帰を向上させるだけでなく、対処可能な市場も拡大させています。特に希少疾病に対する早期承認に対する規制当局の支援は、有望な薬剤の迅速な市場参入をさらに促進しています。最後に、十分な治療を受けていないMPNサブグループを対象とした臨床試験の増加に加え、QOLの向上と生存成績の改善を求める患者の強い支持により、市場環境は再構築されつつあります。これらの動向が相まって、持続的な技術革新が促進され、MPN治療の新たな成長軌道が世界的に開かれています。

セグメント

疾患タイプ（本態性血小板血症、骨髄線維症、ベラ多血症）、薬剤クラス（チロシンキナーゼ阻害剤、ヤヌスキナーゼ阻害剤、代謝拮抗剤、その他の薬剤クラス別）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の32社）

• AbbVie Inc.
• Ajax Therapeutics
• Bristol Myers Squibb
• Celgene Corporation
• Constellation Pharmaceuticals
• CTI BioPharma Corp
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Galena Biopharma Inc.
• Gamida Cell Ltd.
• Incyte Corporation
• Italfarmaco S.p.A.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• PharmaEssentia Corporation
• Sierra Oncology, Inc.
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Myeloproliferative Neoplasms Treatment Market to Reach US$10.5 Billion by 2030

The global market for Myeloproliferative Neoplasms Treatment estimated at US$9.1 Billion in the year 2024, is expected to reach US$10.5 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2024-2030. Essential Thrombocythemia, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Myelofibrosis segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Billion While China is Forecast to Grow at 4.7% CAGR

The Myeloproliferative Neoplasms Treatment market in the U.S. is estimated at US$2.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 4.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Myeloproliferative Neoplasms Treatment Market - Key Trends & Drivers Summarized

What Makes Myeloproliferative Neoplasms a Persistent Therapeutic Challenge?

Myeloproliferative neoplasms (MPNs) represent a complex group of hematologic malignancies that arise from genetic mutations in hematopoietic stem cells, leading to the overproduction of blood cells. The three classic MPN subtypes-polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)-exhibit significant overlap in clinical manifestations, yet demand highly individualized treatment approaches. Chronic disease progression, frequent thrombotic events, and the risk of transformation into acute myeloid leukemia (AML) contribute to the intricate clinical landscape. These variables underscore the persistent therapeutic challenge for hematologists, who must balance symptom control with the prevention of disease progression.

A fundamental complexity lies in the heterogeneity of disease drivers, particularly the presence of mutations in JAK2, CALR, and MPL genes. This genetic variability necessitates precision medicine strategies tailored to specific mutational profiles. The chronic nature of MPNs often requires lifelong management, with therapies evolving as the disease transforms or develops resistance. As understanding of molecular pathogenesis deepens, therapeutic paradigms are shifting away from symptom-focused care toward disease-modifying strategies. This evolving treatment philosophy is reshaping clinical priorities and bolstering demand for targeted therapies that go beyond JAK inhibition alone.

How Are Therapeutic Innovations Reshaping Treatment Strategies?

Recent advancements in MPN therapeutics are centered around a new generation of targeted agents, most notably Janus kinase (JAK) inhibitors. Ruxolitinib and fedratinib have become cornerstones of myelofibrosis treatment, offering effective symptom relief and spleen volume reduction. However, limitations related to cytopenias and resistance have stimulated the pursuit of novel agents with distinct mechanisms of action. These include interferons for early-phase PV and ET, telomerase inhibitors like imetelstat for high-risk myelofibrosis, and BET inhibitors aiming to influence gene expression. These drugs, currently in late-stage clinical trials, promise to expand therapeutic choices for patients resistant to current JAK inhibitors.

Additionally, combination therapies are gaining prominence as a means to overcome resistance and prolong clinical benefit. Research into dual pathway inhibition-such as combining JAK inhibitors with PI3K, BCL-2, or epigenetic modulators-is showing potential for more durable responses. Biomarker-driven drug development is also refining patient selection for novel trials, aiming to personalize therapy based on individual disease biology. These innovations mark a decisive shift toward a more nuanced, stratified approach to MPN treatment, moving the field closer to true disease modification rather than palliation.

Why Is Diagnostic Precision and Patient Monitoring Gaining Centrality?

Advanced diagnostic techniques are becoming instrumental in refining treatment decisions and assessing disease progression. The increasing accessibility of next-generation sequencing (NGS) and molecular profiling is empowering clinicians to accurately classify MPN subtypes and detect high-risk mutations. These tools are particularly valuable in identifying additional mutations-such as ASXL1, SRSF2, and EZH2-that confer poor prognosis, thereby influencing the intensity of therapy and transplant eligibility. Diagnostic precision is no longer limited to initial detection but is now pivotal in guiding treatment adaptation over time.

Furthermore, longitudinal disease monitoring through molecular testing is reshaping how treatment response and progression are assessed. Regular tracking of allele burden, hematologic parameters, and bone marrow fibrosis levels enables early detection of therapeutic resistance and progression to AML. The emergence of measurable residual disease (MRD) assessments also opens new avenues for evaluating treatment efficacy, particularly in the context of clinical trials. This integration of diagnostics into therapeutic decision-making is transforming clinical pathways and is expected to play an increasingly vital role in future treatment algorithms.

What’s Driving the Growth Momentum in the Myeloproliferative Neoplasms Treatment Market?

The growth in the myeloproliferative neoplasms treatment market is driven by several factors rooted in technological advances, end-use transformations, and evolving clinical needs. The accelerated adoption of targeted therapies, particularly JAK inhibitors and emerging second-line agents, is a critical growth catalyst. As resistance to first-generation treatments becomes more prevalent, the pipeline of innovative molecules with differentiated mechanisms of action is gaining commercial momentum. Biopharmaceutical companies are intensifying their focus on developing disease-modifying treatments that can alter the natural history of MPNs, particularly myelofibrosis.

Rising demand from specialized hematology centers and tertiary care institutions is another major growth lever, as these centers increasingly embrace molecular diagnostics and personalized treatment protocols. The integration of precision medicine into standard care is not only enhancing patient outcomes but also expanding the addressable market. Regulatory support for accelerated drug approvals-especially for orphan diseases-has further facilitated faster market entry of promising agents. Lastly, the growing number of clinical trials targeting underserved MPN subgroups, coupled with strong patient advocacy for improved quality of life and survival outcomes, is reshaping the market landscape. Together, these trends are fueling sustained innovation and unlocking new growth trajectories for MPN treatment globally.

SCOPE OF STUDY:

The report analyzes the Myeloproliferative Neoplasms Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Essential Thrombocythemia, Myelofibrosis, Polycythemia Vera); Drug Class (Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie Inc.
• Ajax Therapeutics
• Bristol Myers Squibb
• Celgene Corporation
• Constellation Pharmaceuticals
• CTI BioPharma Corp
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Galena Biopharma Inc.
• Gamida Cell Ltd.
• Incyte Corporation
• Italfarmaco S.p.A.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• PharmaEssentia Corporation
• Sierra Oncology, Inc.
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Myeloproliferative Neoplasms Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis Drives MPN Drug Demand
  • OEM Focus on Targeted Therapies Supports Growth in JAK Inhibitor and Mutation-Specific Treatment Development
  • Increased Diagnosis Through Molecular Testing Boosts Early Intervention and Long-Term Treatment Planning
  • Expansion of Hematology-Oncology Care Infrastructure Enhances Access to Advanced Therapies in MPNs
  • Pipeline Advancements in CALR, MPL, and JAK2 Mutation Inhibitors Drive Innovation in Precision Oncology
  • Rising Demand for Oral Therapies and Home-Based Treatments Improves Patient Compliance and Quality of Life
  • Push for Combination Therapies Accelerates Clinical Trials Involving Immunomodulators and Anti-Fibrotic Agents
  • Regulatory Designations for Orphan Drugs and Breakthrough Therapies Support Fast-Tracked Development
  • Growth in Companion Diagnostic Platforms Enhances Selection of Personalized MPN Therapies
  • Increased Awareness Among Clinicians and Patients Expands Global Diagnosis and Treatment Rates
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Myeloproliferative Neoplasms Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Myeloproliferative Neoplasms Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Essential Thrombocythemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Essential Thrombocythemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Essential Thrombocythemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Myelofibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Myelofibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Myelofibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Polycythemia Vera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Polycythemia Vera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Polycythemia Vera by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Janus Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Janus Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Janus Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Antimetabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• JAPAN
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• CHINA
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• EUROPE
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Myeloproliferative Neoplasms Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• FRANCE
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• GERMANY
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Myeloproliferative Neoplasms Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• INDIA
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Myeloproliferative Neoplasms Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Myeloproliferative Neoplasms Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030
• AFRICA
  • Myeloproliferative Neoplasms Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Myeloproliferative Neoplasms Treatment by Disease Type - Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Disease Type - Percentage Breakdown of Value Sales for Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Myeloproliferative Neoplasms Treatment by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Myeloproliferative Neoplasms Treatment by Drug Class - Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Myeloproliferative Neoplasms Treatment by Drug Class - Percentage Breakdown of Value Sales for Tyrosine Kinase Inhibitors, Janus Kinase Inhibitors, Antimetabolites and Other Drug Classes for the Years 2015, 2025 & 2030

IV. COMPETITION